3 November 2024
Latham Advises Harmony Biosciences Holdings, Inc. in Public Offering of Common Stock by Selling Shareholders
Advising firms
Deal team
10 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Christopher Lueking Lead | Latham & Watkins LLP | Partner | capital markets | Chicago |
| Jonathan Sarna Lead | Latham & Watkins LLP | Partner | capital markets | Chicago |
| KC Sands | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Ryan Hudson | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Teddy Finneran | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Tayler Daniels | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Elizabeth Richards | Latham & Watkins LLP | Partner | regulatory | Washington, D.C. |
| Betty Pang | Latham & Watkins LLP | Partner | regulatory | Bay Area |
| Chad Jennings | Latham & Watkins LLP | Counsel | regulatory | Washington, D.C. |
| Rene de Vera | Latham & Watkins LLP | Partner | tax | Chicago |
7 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 31 (US$31.00 per share)
- What the figure measures
- Per share
- Client
- Harmony Biosciences Holdings, Inc.Issuer
- Counterparties
- Marshman Fund Trust II (Sell-side)
Valor IV Pharma Holdings, LLC (Sell-side)